|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-8-12
|
|
pubmed:abstractText |
LY293111 (LY) is a novel oral anticancer agent with leukotriene B4 receptor antagonist and peroxisome proliferator-activated receptor gamma agonist properties, producing promising results alone and in combination with gemcitabine in pancreatic cancer xenograft models. A phase I study proved that the combination (gemcitabine plus LY) is safe and well tolerated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1528-9117
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
339-43
|
|
pubmed:meshHeading |
pubmed-meshheading:19672152-Adenocarcinoma,
pubmed-meshheading:19672152-Adult,
pubmed-meshheading:19672152-Aged,
pubmed-meshheading:19672152-Aged, 80 and over,
pubmed-meshheading:19672152-Antimetabolites, Antineoplastic,
pubmed-meshheading:19672152-Benzoic Acids,
pubmed-meshheading:19672152-Deoxycytidine,
pubmed-meshheading:19672152-Double-Blind Method,
pubmed-meshheading:19672152-Female,
pubmed-meshheading:19672152-Humans,
pubmed-meshheading:19672152-Male,
pubmed-meshheading:19672152-Middle Aged,
pubmed-meshheading:19672152-Pancreatic Neoplasms,
pubmed-meshheading:19672152-Receptors, Leukotriene B4,
pubmed-meshheading:19672152-Treatment Outcome,
pubmed-meshheading:19672152-United States
|
|
pubmed:articleTitle |
Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas.
|
|
pubmed:affiliation |
Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA. wasif.saif@yale.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
